# Study Exploring the Effect of Crizanlizumab on Kidney Function in Patients With Chronic Kidney Disease Caused by Sickle Cell Disease

> **NCT04053764** · PHASE2 · COMPLETED · sponsor: **Novartis Pharmaceuticals** · enrollment: 58 (actual)

## Conditions studied

- Sickle Cell Disease (SCD)

## Interventions

- **DRUG:** Crizanlizuamb
- **DRUG:** Standard of Care

## Key facts

- **NCT ID:** NCT04053764
- **Lead sponsor:** Novartis Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2019-12-10
- **Primary completion:** 2023-03-20
- **Final completion:** 2023-03-20
- **Target enrollment:** 58 (ACTUAL)
- **Last updated:** 2024-10-09


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04053764

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04053764, "Study Exploring the Effect of Crizanlizumab on Kidney Function in Patients With Chronic Kidney Disease Caused by Sickle Cell Disease". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT04053764. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*